ArticleProstate international2026
Infectious complications after transrectal prostate biopsy in Algeria: A prospective study in a high-resistance setting.
Article in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to assess infectious outcomes and safety of fosfomycin trometamol compared with ciprofloxacin for the prevention of infectious complications following transrectal ultrasound-guided prostate biopsy (TRPB) in a local setting characterized by high fluoroquinolone resistance. Material and methods: This prospective single-center cohort study included 423 consecutive patients undergoing TRPB between February 2023 and December 2025. An initial comparative phase involved 200 patients receiving either ciprofloxacin (n=83) or fosfomycin trometamol (n=117). Fosfomycin was subsequently adopted as the standard prophylactic regimen in an additional 223 patients. Infectious complications occurring within 30 days were recorded. A univariate analysis was performed to explore factors associated with infectious complications. Results: The overall rate of infectious complications was 8.3% (35/423), mainly transient isolated fever (5.2%). Five patients (1.2%) required hospitalization for acute prostatitis. No statistically significant association with infectious complications was observed in the univariate analysis. In the initial comparative phase, no significant difference was observed between ciprofloxacin and fosfomycin regarding infectious outcomes. Conclusions: In a context of high fluoroquinolone resistance, single-dose fosfomycin trometamol may represent a pragmatic prophylactic option, although comparative efficacy cannot be concluded from the present design. Level of Evidence: Level 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.